Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 2Melanoma 2Breast Neoplasms 2Brain Neoplasms 2Thyroid Cancer, Papillary 1Solid Tumors 1Sarcoma 1Salivary Gland Neoplasms 1Rare Tumour 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Noonan Syndrome 6 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Locally Advanced Thyroid Gland Carcinoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × entrectinib × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡